599 related articles for article (PubMed ID: 16920659)
1. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
[TBL] [Abstract][Full Text] [Related]
4. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
[TBL] [Abstract][Full Text] [Related]
5. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
6. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Hu R; Barbault F; Delamar M; Zhang R
Bioorg Med Chem; 2009 Mar; 17(6):2400-9. PubMed ID: 19250835
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
[TBL] [Abstract][Full Text] [Related]
8. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Cichero E; Fossa P
J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
Xu HR; Fu L; Zhan P; Liu XY
SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
[TBL] [Abstract][Full Text] [Related]
10. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
Li Z; Han J; Chen HF
Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
RodrÃguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
12. Quantum study of mutational effect in binding of efavirenz to HIV-1 RT.
Mei Y; He X; Xiang Y; Zhang DW; Zhang JZ
Proteins; 2005 May; 59(3):489-95. PubMed ID: 15789428
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
Vanangamudi M; Poongavanam V; Namasivayam V
Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis.
Pungpo P; Hannongbua S
J Mol Graph Model; 2000 Dec; 18(6):581-90, 601. PubMed ID: 11155314
[TBL] [Abstract][Full Text] [Related]
15. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
16. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
17. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
Wu HQ; Yao J; He QQ; Chen FE
SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
[TBL] [Abstract][Full Text] [Related]
18. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
19. Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.
Cichero E; Cesarini S; Fossa P; Spallarossa A; Mosti L
Eur J Med Chem; 2009 May; 44(5):2059-70. PubMed ID: 19046616
[TBL] [Abstract][Full Text] [Related]
20. A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method.
Srivab P; Hannongbua S
ChemMedChem; 2008 May; 3(5):803-11. PubMed ID: 18338369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
